Bain Capital Life Sciences Fund II, L.P. 13D and 13G filings for Xilio Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-02-17 4:30 pm Purchase | 2025-12-31 | 13G | XILIO THERAPEUTICS INC XLO | Bain Capital Life Sciences Fund II, L.P. | 447,124 8.500% | 120,923 (+37.07%) | Filing |
| 2024-11-14 5:44 pm Purchase | 2024-09-30 | 13G | XILIO THERAPEUTICS INC XLO | Bain Capital Life Sciences Fund II, L.P. | 326,201 11.000% | 229,867 (+238.61%) | Filing |
| 2022-02-14 06:42 am Unchanged | 2021-12-31 | 13G | XILIO THERAPEUTICS INC XLO | Bain Capital Life Sciences Fund II, L.P. | 96,334 4.900% | 0 (Unchanged) | Filing |
| 2021-11-05 5:16 pm Purchase | 2021-10-26 | 13G | XILIO THERAPEUTICS INC XLO | Bain Capital Life Sciences Fund II, L.P. | 96,334 5.100% | 96,334 (New Position) | Filing |